Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.38 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25523333 | 0.85 | IGF1R (0.38) | SCN8AADORA2AADORA1HTTIGF1R | |
| SCHEMBL25523327 | 0.85 | ADORA2A (0.41) | ADORA2AHTR1ATLR7MAOAMAOB | |
| SCHEMBL2082460 | 0.83 | NOS3 (0.45) | SCN8AADORA2AADORA1HTTIGF1R | |
| SCHEMBL30481998 | 0.83 | SCN8A (0.55) | SCN8ACYP3A4CHRM2MAOAMAOB | |
| SCHEMBL23775046 | 0.82 | NPC1 (0.47) | SCN8AMAOAMAOB | |
| SCHEMBL25522228 | 0.81 | TLR7 (0.41) | SCN8AADORA2AHTR1ATLR7CHRM2 | |
| SCHEMBL2261106 | 0.75 | NOS3 (0.41) | ADORA2AADORA1IGF1RFGFR1KDR | |
| SCHEMBL14477280 | 0.75 | CCR1 (0.43) | HTR1ACHRM2 | |
| SCHEMBL2084689 | 0.74 | ADORA2A (0.44) | ADORA2AADORA1HTTIGF1RFGFR1 | |
| SCHEMBL25378467 | 0.74 | HTT (0.50) | SCN8AADORA2AADORA1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | SCN8A 4172/4885ADORA2A 4422/4885ADORA1 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.